Where does MBX Biosciences, Inc.'s cash flow data come from?

Every line is extracted from MBX Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$86.61M-17.9%	-$86.97M-40.5%	-$80.5M-45.9%	-$77.02M-63.2%	-$73.47M-88.6%
Depreciation and amortization	$324K-3.3%	$337K+10.1%	$335K+15.9%	$335K+15.9%	$335K—
Stock-based compensation	$12.32M+127%	$8.68M+66.2%	$7.51M+58.0%	$6.46M—	$5.44M—
Change in accounts payable	$3.08M+63.0%	-$2.46M-163%	-$950K-128%	$3.32M+164%	$1.89M+141%
Change in accrued liabilities	$1.63M-62.4%	$7.05M+109%	$2.6M-23.3%	$1.71M-24.0%	$4.34M+1,251%
Change in other assets	$5.07M+358%	$2.7M+14.9%	$1.72M-34.8%	$745K—	$1.11M—
Change in operating lease liabilities	——	——	——	$401K—	-$158K—
Net cash from operating activities	-$77.48M-16.2%	-$79.95M-46.2%	-$77.69M-56.0%	-$70.81M—	-$66.65M—
Capital expenditures	$2.34M+270%	$1.93M+121%	$1.23M+46.7%	$886K—	$631K—
Net cash from investing activities	-$184.03M-6.5%	-$83.71M+47.9%	-$21.08M+82.8%	-$138.92M—	-$172.8M—
Proceeds from issuance of common stock	$4.85M+1,849%	$2.42M+456%	$1.66M+541%	$1.53M—	$249K—
Net cash from financing activities	$277.02M+18.4%	$189.59M-19.1%	$189.15M-19.3%	$237.14M—	$234.06M—
Net increase (decrease) in cash	——	——	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$2.85M-24.4%	$3.61M+23.3%	$4.45M+109%	$4.31M—	$3.77M—
Depreciation	$324K-3.3%	$337K+10.1%	$335K+15.9%	$335K+15.9%	$335K—
Operating lease liabilities	——	——	——	$401K—	-$158K—
Increase (Decrease) in Other Operating Assets	——	——	——	——	$0-100%
Increase (Decrease) in Prepaid Expense and Other Assets	$5.07M+358%	$2.7M+14.9%	$1.72M-34.8%	$745K—	$1.11M—
Non Cash Operating Lease Expense	$138K+25.5%	$133K+25.5%	$128K+23.1%	$123K—	$110K—
Payments Of Stock Issuance Costs	$1.15M-71.7%	$771K-81.0%	$581K—	$2.25M—	$4.06M—
Net proceeds from sales of subsidiary shares	——	——	——	——	——
Accrued payables for capital expenditures	——	——	——	——	——
Deferred Public Offering Costs Included In Accounts Payable And Accrued Expenses	——	——	——	——	——
Increase Decrease In Operating Lease Liability	——	——	——	$401K—	-$158K—
Vesting Of Early Exercised Stock Options	——	——	——	——	——
Free cash flow	-$79.82M-18.6%	-$81.88M-47.4%	-$78.91M-55.9%	-$71.7M—	-$67.28M—
Free cash flow	-$79.82M-18.6%	-$81.88M-47.4%	-$78.91M-55.9%	-$71.7M—	-$67.28M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does MBX Biosciences, Inc.'s cash flow data come from?: Every line is extracted from MBX Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.